Author:
Stanić Jelena,Stanković Vesna,Voštinić Snežana,Nikitović Marina
Abstract
Cancer survivors often face adverse effects of treatment, which have a significant impact on morbidity and mortality. Normal-tissue side effects following radiotherapy (RT), as one of therapeutic modalities, are common and may seriously affect quality of life which is especially important in long-term prostate cancer (PC) survivors. Upgrading in our knowledge in radiation biology have led to the better understanding that genetics plays a significant role in determining a patient's predisposition to developing late RT toxicity, leading to the new field of research called "radiogenomics". With the evolution of DNA sequencing technologies and genomic analysis, radiogenomics made an appearance as a state-of-the-art science in the field of personalized medicine with the goal of detection the genetic determinants RT adverse reactions. A single-nucleotide polymorphism (SNPs) - based assay could be used to predict the risk of RT side effects along with clinical features and treatment factors. Several SNPs have been identified that are associated with late radiation-induced morbidity in PC patients. Most importantly, these SNPs make up genes expressed in the tissues that are likely at the root of these symptoms, including the bladder, rectum, and small intestine, which are most exposed in PC RT. Furthermore, genome-wide association studies are likely to lead to an increasing number of genetic polymorphisms that can predict long-term RT complications. Finally, radiogenomics attempts to predict which PC patients will show radiosensitivity, so that radiation oncologists, as well as surgeons, can change treatment accordingly in order to reduce side effects or increase the RT effectiveness.
Publisher
Centre for Evaluation in Education and Science (CEON/CEES)
Reference29 articles.
1. Siegel R.L, Miller K.D, Jemal A. Cancer statistics. 2020. CA Cancer J Clin. 2020; 70:7-30;
2. Dulaney CR, Osula DO, Yang ES, Rais-Bahrami S. Prostate Radiotherapy in the Era of Advanced Imaging and Precision Medicine. Prostate Cancer. 2016;2016:4897515;
3. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, et al. Bethesda, MD: 2016. Apr, SEER Cancer Statistics Review, 1975-2013, National Cancer Institute. http:// seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site;
4. Schack LMH, Petersen SE, Nielsen S, Lundby L, Høyer M, Bentzen L, et al. Validation of genetic predictors of late radiation-induced morbidity in prostate cancer patients. Acta Oncol. 2017;56(11):1514-21;
5. Bentzen SM, Constine LS, Deasy JO, Eisbruch A, Jackson A, Marks LB, et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys. 2010;76:S3-S9;